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cally significant (α ≤ 0.05). In contrast, 47 medicines had an average BPS price 
after CAP significantly lower or equal to the average BPS price before CAP (α ≤ 
0.05). ConClusions: It is concluded that this CMED legislation is economic and 
social efficient.
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objeCtives: The aging of the population and the increase of chronic disease 
patients represent the current medical and socio-economic challenges. In 2008, 
facing considerable increase of medicines cost in nursing homes (NH) in the 
canton of Vaud (Switzerland), professionals around the resident were invited to 
develop a collaborative pharmacy practice model derived from the successful 
experimentation in the canton of Fribourg. The intervention called Quality Circle 
in NH is an evidence-based program with a direct influence on the prescriber, that 
promotes team based care and clinical guidelines. The model has showed sustain-
able evidence of the cost containment of medicines without affecting the quality of 
care. The objective of this study was to assess the first results of economic impact 
of the program in NH engaged between 2009 and 2012. Methods: Individual 
data by NH resident was derived from community pharmacists’ invoice and from 
resident admission data. The evolution of the daily mean drug cost per resident 
was compared to the evolution of the daily mean drug cost of the population 
over 65 years old in primary care from cantonal pharmacy invoice (Swiss Health 
Observatory, OBSAN). Results: Between 2009 and 2012,13 NH were entered into 
the program (601/6’492 beds, 9.3%), between 9 and 11 NH were monitored. In 2012, 
the mean age of residents was 88 (SD 7.3) years old; 78% were women. From 2009 
to 2012 the daily mean drug cost per resident of the program decreased to 10.3% 
from 6.8 to 6.1 EUR, representing a clear reduction compared to cantonal invoice 
that record an increase of 0.59%. ConClusions: The monitoring of the program 
shows first positive results due to the reduction of drug costs. Nevertheless, this 
model has an operating cost. The next step will be to determine the break even 
point of the intervention.
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objeCtives: To assess the patterns and factors associated with prescription 
of FDA classified C, D and X category drugs (unsafe medications) during preg-
nancy. Methods: Cross-sectional analysis was conducted of pregnant women aged 
20 and 49 years using data from the Medical Expenditure Panel Survey (MEPS) for the 
years 2009 and 2011. Difference in the demographic variables, socioeconomic status, 
access to health care, and chronic conditions were tested for the use of safe medi-
cations. All analyses accounted for the complex survey design of MEPS. Results: 
The study sample consisted of 1603 pregnant women (whites [595 (58.8%)], married 
[924 (66.3%)], employed [918 (64.5%)], no chronic illness [1103 (65%)]). A total of 413 
(28.3%) women utilized medication of FDA category CDX. The use of the category 
C medications was highest [337 (23.4%)] drugs followed by category D [101 (6.9 %)], 
and category X [64 (4.4)]. Women with chronic illness [adjusted Odds Ratio (aOR) = 
1.61; 95% CI = 1.03, 2.52, P < 0.001], having fair or poor perceived health status (aOR = 
1.95; 95% CI= 1.15, 3.31, P < 0.05), doing regular physical activity (aOR = 1.50; 95% CI= 
1.12, 2.01, P < 0.01) were more likely to receive unsafe medication, while pregnant 
women with less than higher secondary education (OR = 0.30; 95% CI = 0.11,0. 81, 
P < 0.05), with near poor (aOR: 0.53, 95% CI: 0.31, 0.91, P< 0.05) or middle income (aOR: 
0.62, 95% CI: 0.40, 0.95, P < 0.05), were less likely to receive unsafe medications. There 
were no differences rates of unsafe medications use by age, race, marital status, 
employment status, mental health, and smoking status. ConClusions: Nearly 
one-third of all pregnant women used FDA category CDX drugs. Interventions should 
be carried out to reduce utilization of FDA CDX especially among the women with 
chronic conditions and poor health status.
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objeCtives: A model was designed to evaluate infertility treatment protocols and 
examines the medical and pharmacy budget impact from a patient and health 
plan perspective. Methods: An Excel-based platform (Microsoft Excel 2010) was 
designed to model the cost and expected number of pregnancies associated with 
the following advanced infertility treatments: natural cycle intrauterine insemina-
tion (IUI), IUI with clomiphene citrate (IUI-C), IUI with gonadotropins (IUI-G), in vitro 
fertilization (IVF) and IVF with intracytoplasmic injection (IVF+ICSI). The model is 
designed to customize inputs within key parameters including population, treat-
ment strategies and health plan coverage. Standard fertility treatment strategy can 
choose to enter one of five standard first line treatment pathways including IUI, 
IUI-C, IUI-G, IVF or IVF+ICSI. Fast track fertility treatment strategy does not include 
the use of IUI-G. Health plan coverage allows end user to input drug coverage (yes/
no, copayment per cycle and patient coinsurance) and procedure coverage (yes/no, 
number of cycles covered, copayment, number of covered doctor visits per cycle 
and patient coinsurance). Results: Default model population of women initiating 
fertility treatment is 1,555. The total cost to the health plan per year (health plan 
years corrected age will be presented in November 2014 with follow-up comple-
tion and data release from Government database by August 2014. ConClusions: 
Preterm infants showed high services use including hospitalisation, with associated 
high costs. Costs vary by patient characteristics and costing approach. This study’s 
results should inform effective resource planning of neonatal health services and 
development of future prevention interventions aimed at preterm birth.
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objeCtives: Topical testosterone agents (TTAs) are commonly used to raise low 
serum levels of testosterone in men. After initiating at a recommended starting dose 
(RSD), patients may undergo dose titration to achieve an appropriate maintenance 
dose. The objective of this study was to compare daily maintenance doses and 
costs of treatment with TTAs from US payer perspective in adult men diagnosed 
with Hypogonadism (HG). Methods: Adult men with a HG-associated diagno-
ses initiated at the RSD with Axiron® (Lilly USA, LLC; RSD 60mg per day; N= 209), 
AndroGel® 1% (AbbVie Inc.; 50mg per day; N= 614), AndroGel® 1.62% (AbbVie Inc.; 
40.5mg per day; N= 235), or Testim® (Auxilium Pharmaceuticals, Inc.; 50mg per day; 
N= 558) between January 1, 2011 and March 31, 2012 were identified in a database 
of commercially insured beneficiaries. Patients were required to have continuous 
eligibility and no claims of the index therapy in 12 months prior to and at least 1 
month of continuous eligibility following initiation. Baseline demographic charac-
teristics, Charlson Comorbidity Index (CCI), comorbidities, and testosterone use 
were compared using chi-squared test for categorical variables and Wilcoxon rank-
sum test for continuous variables. Mean dose was estimated per-person per-day 
(PPPD). Risk-adjusted dose and payer costs PPPD were estimated with a generalized 
linear model. Results: Maintenance dose was attained at month 4. Mean dose 
PPPD in month 4 was 68.45mg, 56.68 mg, 51.18mg, and 59.24mg and risk-adjusted 
dose PPPD was 113.3%, 113.5%, 126.3%, and 118.7% of RSD for Axiron, AndroGel 
1% (non-significant vs. Axiron), AndroGel 1.62% (p< 0.001 vs. Axiron), and Testim 
(p= 0.047 vs. Axiron), respectively. Risk-adjusted third-party payer costs PPPD were 
$7.49, $9.49, $10.39, and $9.59 (all p< 0.001 vs. Axiron), respectively. ConClusions: 
Maintenance dose as a proportion of RSD was the least among Axiron and AndroGel 
1% patients, while third-party payer costs for the maintenance dose were lowest 
among Axiron patients.
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objeCtives: The aim of this work is measure the efficiency of public medicine 
purchase considering competitive markets applied by the rule that establishes 
PMVG. Methods: The competitive market was defined as more than 5 (five) phar-
maceutical manufactories. Two lists were built, one with PMVG (PMVG databank), 
established by CMED, and the other list contains the public prices acquisitions 
before and after the enacted CAP legislation (Health Price Bank – BPS databank). The 
lists were separated in two groups. The first contains the prices of PMVG databank 
and BPS databank between 2004 and 2006 (group 1), and the second complains 
the prices for the period between 2007 and 2012 (group 2). The comparison of two 
groups, before CAP (group 1) and after CAP (group 2), was conducted by Student 
t-test one-tailed of the mean medicine prices (significance level of 5%, assuming 
unequal variances). Results: The list resulted in a selection of 29 medicines. Six 
(6) medicines had an average BPS price before CAP less than or equal to the aver-
age BPS price after CAP, however, only 1 was statistically significant (α ≤ 0.05). In 
contrast, 23 medicines had an average BPS price after CAP significantly lower or 
equal to the average BPS price before CAP, but only 5 (five) no statistically significant 
(α ≤ 0.05). ConClusions: For competitive market we have observed efficiency loss 
by application of CMED legislation.
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objeCtives: The aim of this work is measure the efficiency of this rule that estab-
lished PMVG for public medicine purchase. Methods: Two lists were built, one 
with PMVG (PMVG databank), established by CMED, and the other list contains 
the public prices acquisitions before and after the enacted CAP legislation (Health 
Price Bank – BPS databank). The lists were separated in two groups. The first con-
tains the prices of PMVG databank and BPS databank between 2004 and 2006 
(group 1), and the second complains the prices for the period between 2007 and 
2012 (group 2). The comparison of two groups, before CAP (group 1) and after CAP 
(group 2), was conducted by Student t-test one-tailed of the mean medicine prices 
(significance level of 5%, assuming unequal variances). Results: CMED imple-
mented The Price Adequacy Coefficient (CAP) by publishing the Resolution CMED 
nº 04 on 18thof December of 2006. It is a mandatory minimum discount to be 
applied by pharmaceutical companies and distributors in the Factory Price of 
medicines (PF) authorized, resulting on a public price cap (PMVG). There is no 
evidence of the efficiency, or the real need for this regulatory activity performed 
by CMED geared to the drug public acquisitions. The list resulted in a selection of 
68 medicines. Fourteen (14) medicines had an average BPS price before CAP less 
than or equal to the average BPS price after CAP, however, only 4 were statisti-
